Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The apicoplast is an essential, non-photosynthetic organelle derived from a secondary endosymbiotic event involving an algal ancestor. Its protein synthesis machinery encompasses both the translation apparatus inside the apicoplast (including ribosomes, tRNAs, translation factors, aminoacyl-tRNA synthetases, and specialized proteins for tRNA modification[6][7]), as well as the multistep import systems required to traffic nuclear-encoded proteins from the cytosol into the organelle[1][9][4]. Unlike most other eukaryotic organelles, virtually all apicoplast proteins are encoded in the parasite nucleus and post-translationally imported, relying on ER-associated translocation machinery and ubiquitylation systems that are evolutionarily adapted for protein import rather than protein destruction[1][4][9]. The apicoplast protein synthesis and import systems are crucial for parasite survival, as they underpin metabolic pathways such as fatty acid synthesis, isoprenoid precursor biosynthesis, iron-sulfur cluster assembly, and some aspects of heme synthesis[8][5][3]. Many components, including the ribosomal machinery, caseinolytic protease (Clp) complex[2], and RNA-binding RAP proteins[7], are parasite-specific and represent validated therapeutic targets. The apicoplast protein synthesis machinery is a collective term for the translation, import, and degradation systems that are essential for the function of the apicoplast organelle in apicomplexan parasites. Its unique evolutionary origins make it an outstanding target for anti-parasitic drug development, with several components already validated both genetically and pharmacologically. The machinery consists of multiple molecular classes, including enzymes, transporters, chaperones, and RNA-binding proteins, orchestrating protein synthesis and trafficking for parasite survival, with no direct human analogy[8][2][7][1][4][6][3][9][10][5].
Inhibition of protein synthesis by blocking translation (ribosome-targeting antibiotics) Prevention of organelle biogenesis and function via inhibition of ClpP protease activity (leading to parasite death) Disruption of tRNA modification, compromising translation fidelity and stability Inhibition of protein import or trafficking, depriving organelle of essential proteins
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apicoplast protein synthesis machinery (None standard; commonly referenced as apicoplast translation/import machinery, but no definitive abbreviation.).